The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients

BMC Cancer

Kashif Shafique²  Michael J Proctor⁴  Donald C McMillan⁴  Hing Leung⁵  Karen Smith¹  Billy Sloan³  David S Morrison³ 

[1] Department of Clinical Biochemistry, Royal Infirmary, Glasgow G4 0SF, UK

[2] Department of Community Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan

[3] West of Scotland Cancer Surveillance Unit, University of Glasgow, 1 Lilybank Gardens, Glasgow G12 8RZ, UK

[4] University Department of Surgery, Faculty of Medicine, University of Glasgow, Royal Infirmary, Glasgow G31 2ER, UK

[5] Beatson Institute for Cancer Research, Garscube Estate Switchback Road Bearsden, Glasgow G61 1BD, UK

关键词: PSA;    Prognosis;    Prostate cancer;    mGPS;   

Others  :  1079698
DOI  :  10.1186/1471-2407-13-292

 received in 2013-03-04, accepted in 2013-06-13,  发布年份 2013

【 摘 要 】

Background

As the incidence of prostate cancer continues to rise steeply, there is an increasing need to identify more accurate prognostic markers for the disease. There is some evidence that a higher modified Glasgow Prognostic Score (mGPS) may be associated with poorer survival in patients with prostate cancer but it is not known whether this is independent of other established prognostic factors. Therefore the aim of this study was to describe the relationship between mGPS and survival in patients with prostate cancer after adjustment for other prognostic factors.

Methods

Retrospective clinical series on patients in Glasgow, Scotland, for whom data from the Scottish Cancer Registry, including Gleason score, Prostate Specific Antigen (PSA), C-reactive protein (CRP) and albumin, six months prior to or following the diagnosis, were included in this study.

The mGPS was constructed by combining CRP and albumin. Five-year and ten-year relative survival and relative excess risk of death were estimated by mGPS categories after adjusting for age, socioeconomic circumstances, Gleason score, PSA and previous in-patient bed days.

Results

Seven hundred and forty four prostate cancer patients were identified; of these, 497 (66.8%) died during a maximum follow up of 11.9 years. Patients with mGPS of 2 had poorest 5-year and 10-year relative survival, of 32.6% and 18.8%, respectively. Raised mGPS also had a significant association with excess risk of death at five years (mGPS 2: Relative Excess Risk = 3.57, 95% CI 2.31-5.52) and ten years (mGPS 2: Relative Excess Risk = 3.42, 95% CI 2.25-5.21) after adjusting for age, socioeconomic circumstances, Gleason score, PSA and previous in-patient bed days.

Conclusions

The mGPS is an independent and objective prognostic indicator for survival of patients with prostate cancer. It may be useful in determining the clinical management of patients with prostate cancer in addition to established prognostic markers.

【 授权许可】

   
2013 Shafique et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Wilt TJ: Radical prostatectomy versus observation for localized prostate cancer. NEJM 2012, 367:203-213.
• [2]Castelli T, Cimino S, Magno C, Morgia G: Molecular markers for prostatic cancer. Front Biosci 2010, 2:641-656.
• [3]Huang HC, Zheng S, VanBuren V, Zhao Z: Discovering disease-specific biomarker genes for cancer diagnosis and prognosis. Technol Cancer Res Treat 2010, 9:219-230.
• [4]Verhagen PC, Tilanus MG, de Weger RA, van Moorselaar RJ, van den Tweel JG, Boon TA: Prognostic factors in localised prostate cancer with emphasis on the application of molecular techniques. Eur Urol 2002, 41:363-371.
• [5]Elsberger B, Lankston L, McMillan DC, Underwood MA, Edwards J: Presence of tumoural C-reactive protein correlates with progressive prostate cancer. Prostate Cancer Prostatic Dis 2011, 14:122-128.
• [6]Vasto S, Carruba G, Candore G, Italiano E, Di BD, Caruso C: Inflammation and prostate cancer. Future Oncol 2008, 4:637-645.
• [7]McMillan DC, McMillan DC: The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev 2012. Epub- Ahead of Print
• [8]Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, et al.: C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 2008, 112:2377-2383.
• [9]Prins RC, Rademacher BL, Mongoue-Tchokote S, Alumkal JJ, Graff JN, Eilers KM, et al.: C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol 2012, 30:33-37.
• [10]Saito K, Kihara K, Saito K, Kihara K: Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol 2012. Epub- Ahead of Print
• [11]Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, Morrison DS: Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow inflammation outcome study. Prostate Cancer Prostatic Dis 2012, 15:195-201.
• [12]Sogani PC, Israel A, Lieberman PH, Lesser ML, Whitmore WF Jr: Gleason grading of prostate cancer: a predictor of survival. Urology 1985, 25:223-227.
• [13]Brewster DH, Clark DI, Stockton DL, Munro AJ, Steele RJ: Characteristics of patients dying within 30 days of diagnosis of breast or colorectal cancer in Scotland, 2003–2007. Br J Cancer 2011, 104:60-67.
• [14]The Scottish Government: Using the Scottish index of multiple deprivation 2004: guidance. Scottish Government; 2006. http://www.scotland.gov.uk/Publications/2005/01/20458/49127 webcite
• [15]Proctor MJ, Talwar D, Balmar SM, O’Reilly DS, Foulis AK, Horgan PG, et al.: The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow inflammation outcome study. Br J Cancer 2010, 103:870-876.
• [16]Dickman PW, Coviello E, Hills M: Estimating and modelling relative survival. The Stata Journal 2008.
• [17]McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC: Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006, 77:127-129.
• [18]Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, et al.: Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clinl Oncol 2009, 27:3437-3444.
• [19]Roxburgh CS, McMillan DC: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010, 6:149-163.